- Home
- NBTX vs GNLX Comparison
NBTX vs GNLX Comparison
Compare NBTX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- GNLX
- Stock Information
- Founded
- NBTX 2003
- GNLX 2001
- Country
- NBTX France
- GNLX United States
- Employees
- NBTX N/A
- GNLX N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- NBTX Health Care
- GNLX Health Care
- Exchange
- NBTX Nasdaq
- GNLX Nasdaq
- Market Cap
- NBTX 201.9M
- GNLX 184.4M
- IPO Year
- NBTX 2020
- GNLX 2023
- Fundamental
- Price
- NBTX $3.75
- GNLX $4.81
- Analyst Decision
- NBTX Strong Buy
- GNLX Strong Buy
- Analyst Count
- NBTX 1
- GNLX 4
- Target Price
- NBTX $12.00
- GNLX $18.25
- AVG Volume (30 Days)
- NBTX 8.9K
- GNLX 331.4K
- Earning Date
- NBTX 09-18-2024
- GNLX 03-31-2025
- Dividend Yield
- NBTX N/A
- GNLX N/A
- EPS Growth
- NBTX N/A
- GNLX N/A
- EPS
- NBTX N/A
- GNLX N/A
- Revenue
- NBTX $45,220,186.00
- GNLX $8,000.00
- Revenue This Year
- NBTX N/A
- GNLX N/A
- Revenue Next Year
- NBTX N/A
- GNLX N/A
- P/E Ratio
- NBTX N/A
- GNLX N/A
- Revenue Growth
- NBTX 526.17
- GNLX N/A
- 52 Week Low
- NBTX $2.76
- GNLX $1.60
- 52 Week High
- NBTX $7.51
- GNLX $8.67
- Technical
- Relative Strength Index (RSI)
- NBTX 53.25
- GNLX 58.52
- Support Level
- NBTX $3.60
- GNLX $4.62
- Resistance Level
- NBTX $3.95
- GNLX $5.76
- Average True Range (ATR)
- NBTX 0.19
- GNLX 0.57
- MACD
- NBTX -0.01
- GNLX -0.03
- Stochastic Oscillator
- NBTX 38.18
- GNLX 59.96
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.